Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies
Multiple considerations are essential to address the main challenges of dose flexibility and patient adherence in pediatric drug development, particularly for oncology. Mini-tablets, 2 mm in diameter, were manufactured using a rotary tablet press at a set weight and compression force level. The physical characteristics were consistent for mini-tablets throughout multiple batches. Polymeric amorphous solid dispersion (ASD) was used as a solubility enhancing technique to increase solubility and exposure of lapatinib. The effects of the polymeric excipient and disintegrant on drug release properties were investigated. While having a lower apparent solubility and shorter storage stability, hydroxypropyl methylcellulose E3 (HPMCE3) formulation provided a higher percentage of drug release compared to hydroxypropyl methylcellulose phthalate (HPMCP). The intermolecular interaction within the ASD system plays a role in the level of apparent solubility, physical stability, and concentration of free drug available in an aqueous environment. Juvenile porcine models at two different weight groups (10 and 20 kg) were used to obtain the pharmacokinetic parameters of lapatinib. While the dose-normalized exposure of drug was found to be lower in the pig study, the dose flexibility of mini-tablets enabled a constant dose level to be administered to achieve equivalent plasma concentration-time profiles between the two groups. This linear scaling in the amount of drug in pediatric and adult population has also been observed in human clinical studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 22(2021), 1 vom: 08. Jan., Seite 40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lavan, Monika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0VUA21238F |
|---|
| Anmerkungen: |
Date Completed 26.03.2021 Date Revised 26.03.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1208/s12249-020-01891-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319807037 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319807037 | ||
| 003 | DE-627 | ||
| 005 | 20231225172230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-020-01891-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319807037 | ||
| 035 | |a (NLM)33417081 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lavan, Monika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2021 | ||
| 500 | |a Date Revised 26.03.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Multiple considerations are essential to address the main challenges of dose flexibility and patient adherence in pediatric drug development, particularly for oncology. Mini-tablets, 2 mm in diameter, were manufactured using a rotary tablet press at a set weight and compression force level. The physical characteristics were consistent for mini-tablets throughout multiple batches. Polymeric amorphous solid dispersion (ASD) was used as a solubility enhancing technique to increase solubility and exposure of lapatinib. The effects of the polymeric excipient and disintegrant on drug release properties were investigated. While having a lower apparent solubility and shorter storage stability, hydroxypropyl methylcellulose E3 (HPMCE3) formulation provided a higher percentage of drug release compared to hydroxypropyl methylcellulose phthalate (HPMCP). The intermolecular interaction within the ASD system plays a role in the level of apparent solubility, physical stability, and concentration of free drug available in an aqueous environment. Juvenile porcine models at two different weight groups (10 and 20 kg) were used to obtain the pharmacokinetic parameters of lapatinib. While the dose-normalized exposure of drug was found to be lower in the pig study, the dose flexibility of mini-tablets enabled a constant dose level to be administered to achieve equivalent plasma concentration-time profiles between the two groups. This linear scaling in the amount of drug in pediatric and adult population has also been observed in human clinical studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amorphous dispersion | |
| 650 | 4 | |a Juvenile porcine model | |
| 650 | 4 | |a Mini-tablets | |
| 650 | 4 | |a Pediatric drug delivery | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 7 | |a Tablets |2 NLM | |
| 650 | 7 | |a Lapatinib |2 NLM | |
| 650 | 7 | |a 0VUA21238F |2 NLM | |
| 700 | 1 | |a Wang, Xueqi |e verfasserin |4 aut | |
| 700 | 1 | |a McCain, Robyn |e verfasserin |4 aut | |
| 700 | 1 | |a Jannasch, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Hostetler, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Byrn, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Knipp, Gregory |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d 2000 |g 22(2021), 1 vom: 08. Jan., Seite 40 |w (DE-627)NLM126699429 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:1 |g day:08 |g month:01 |g pages:40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12249-020-01891-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 1 |b 08 |c 01 |h 40 | ||